• The Journal of the Korea Contents Association
• /
• v.16 no.5
• /
• pp.601-611
• /
• 2016

As oral trial principle and civil participation in criminal trials spread, the environment of Korean courtroom is in need of a systematic introduction of trial presentation which can supplement with the oral trial presentation's weakness. Therefore this study analyzes the definition, types, and effectiveness of trial presentation, considering characters of the Korean court's environment. As for following research step, the most widely used trial presentation softwares in the USA and Korea are analyzed and compared in consideration of the particularity of the trial presentation. Based on this analysis, this study suggested elements to be included in the presentation software optimized for Korean court's environment as follows: 1. Ease of the insertion of various forms and media, 2. Appropriate limitation of the spectrum for graphic style, 3. Ease of use of graphics tools, 4. System functions. Such a suggestion was proposed not only to enhance the clarity, accuracy, effectiveness in developing insistence and delivery of content, but also promote aesthetic quality and consistency of presentation's visual communication aspect.

• The Korean Society of Law and Medicine
• /
• v.17 no.2
• /
• pp.125-144
• /
• 2016

All forms of Clinical trial should be fully equipped with protection systems for experimental subjects considering their uncertainty and various risks. Existing laws have some regulations in pharmaceutical affairs act and medical device act. Nonetheless, there is a limit to protect the subjects considering law objective to perform administration of medicine. Furthermore, the clinical trial on minor has no direct regulations in pharmaceutical affairs act, but prescribes certain portion in clinical trial assessment guideline on infants or medicine clinical trial management standard, however there is a limit because that is just recommendation not having legal effectiveness. The legislative solution would be possible for legal problems of clinical trial on minor by examining treatment system on minor in organ transplant act and clinical trial on minor in other foreign laws stronger than usual medical practice in terms of degree of human body invasion. I suppose that the control system of clinical trial being done focusing on the pharmaceutical affairs act, medical device act and other guidelines in existing laws system should be resolved by legislating 'trial subject protection law', in addition, this would be well balanced in organ transplant act on protection system of minor organ donors. Furthermore, the judgement on the consent ability and spontaneity in clinical trial on minor should be judged considering maturity and mentality of minor by clinical trial institutional review board based on legislative solution mentioned above.

• Proceedings of the Korean Society for Bioinformatics Conference
• /
• 2005.09a
• /
• pp.85-90
• /
• 2005

In this paper, firstly we report experimental results on applying information extraction (IE) methodology to the task of summarizing clinical trial design information in focus on ‘Compared Treatment’, ‘Endpoint’ and ‘Patient Population’ from clinical trial MEDLINE abstracts. From these results, we have come to see this problem as one that can be decomposed into a sentence classification subtask and an IE subtask. By classifying sentences from clinical trial abstracts and only performing IE on sentences that are most likely to contain relevant information, we hypothesize that the accuracy of information extracted from the abstracts can be increased. As preparation for testing this theory in the next stage, we conducted an experiment applying state-of-the-art sentence classification techniques to the clinical trial abstracts and evaluated its potential in the original task of the summarization of clinical trial design information.

• Transactions of Materials Processing
• /
• v.8 no.2
• /
• pp.127-134
• /
• 1999

This study suggests the practical method which can reduce the lead time of the field trial and design of the dies. The virtual manufacturing, with which the die design is evaluated by computer analysis, reveals the impropriety of a design before die makings. Three methods for reducing the die making process occupying over 60% of the automotive development are like follows: First, the crack and wrinkle occurrence can be prevented by virtually adjusting the blank holding force and drawbead force with a computer simulation. Second, the parts which can not remove the forming defects in spite of the adjustment of forming parameters need to modify the part geometry or punch temporary shape. Third, the simulation before field trial, and field trial simulation can be effectively used in die design.

• Journal of Korean Society for Quality Management
• /
• v.39 no.2
• /
• pp.329-336
• /
• 2011

The purpose of Phase I clinical trial is to identify the maximum tolerated dose with specific toxicity rate. The standard TER design does not guarantee the pre-specified toxicity rate. It depends on the dose-toxicity curves. Therefore it is necessary to check the expected toxicity rate of various dose-toxicity curves before we conduct clinical trials. We developed TERAplusB library to help this situation, especially in cancer research. This package will help design the cancer clinical trial. We can compare the expected toxicity rates, the expected number of patients, and the expected times calculated with various dose-toxicity curves. This process will help find the best clinical trial design of the proposed drug.

• Journal of East-West Nursing Research
• /
• v.17 no.1
• /
• pp.9-15
• /
• 2011

Purpose: The purpose of this study was to investigate recognition and knowledge regarding clinical trials, in particular, after a clinical trial education program (CTEP) among student nurses. Methods: A cross-sectional survey design of 215 student nurses at a university in Seoul was used with structured questionnaires. Results: Respondents had a high level of need for clinical trial and moderate levels in favorable image, safety, and need for education regarding clinical trial. The respondents who had participated in the CTEP felt the clinical trial more favorable and safer than those who did not. However, there were no significant differences in necessity of clinical trials and need for education regarding clinical trial between the CTEP participation and no participation groups. Respondents had a high level of knowledge about clinical trial, even though half of the respondents misunderstood that the physician can convince the subject to participate in clinical trial. There was no significant difference in knowledge level between groups. One third of the respondents had an intention to work in the area related to clinical trial because of aptitude or future prospect. Conclusion: The results of this study demonstrated that the CTEP might have an effect on student nurses' recognition rather than knowledge. The CTEP should be therefore developed targeting specific areas of misconceptions and recognition changes.

• The Journal of Internal Korean Medicine
• /
• v.28 no.2
• /
• pp.363-376
• /
• 2007

Objectives : This study was undertaken to learn what should be considered in a good clinical trial investigating a herbal medicine as an antidepressant. Methods : Five well-designed clinical trials published from 2000 to 2006 investigating SJWE in depressive disorder were selected. The trials were reviewed and compared in terms of methodology such as trial design, patient selection, efficacy & safety evaluation, and so on. On the basis of this review of the trials and the regulations and guidelines of KFDA, we suggest some points to be considered for a good clinical trial of a herb for depression. Results : Although every trial had its own unique design, procedure, objectives and so on, all trials used randomizing and double blinding methods. If there is no ethical problem, a placebo-controlled design should be considered in a herbal antidepressant clinical trial for depression. Conclusions : Some points to be considered in an optimal & good clinical trial for an antidepressive herbal medicine were suggested as follows: 1) randomizing and double blinding manner is essential, 2) if there is no ethical problem, placebo control design should be considered, 3) the trial period should be 6 weeks, 4) out-patients will be recruited as subjects, 5) investigators will be well-trained psychiatrists or medical doctors, 6) the number of subjects should be calculated by statistical methods, 7) subjects should be diagnosed by DSM-IV criteria, 8) subjects who have current risk of committing suicide should be excluded, etc.

• Publications of The Korean Astronomical Society
• /
• v.24 no.1
• /
• pp.65-81
• /
• 2009

We present the performance test results of VLBI Correlation Subsystem (VCS) trial product which was being developed for 1 year from August 2007. It is a core component of Korea-Japan Joint VLBI Correlator (KJJVC). The aim for developing VCS trial product is to improve the performance of VCS main product to reduce the efforts and cost, and to solve the design problems by performing the preliminary test of the manufactured trial product. The function of VCS trial product is that it is able to process the 2 stations-1 baseline, 8 Gbps/station speed, 1.2 Gbps output speed with FX-type. VCS trial product consists of Read Data Control Board (RDC), Fourier Transform Board (FTB), and Correlation and Accumulation Board (CAB). Almost main functions are integrated in the FTB and CAB board. In order to confirm the performance of VCS trial product functions, the spectral analysis, delay compensation and correlation processing experiments were carried out by using simulation and real observation data. We found that the overflow problem of re-quantization after FFT processing was occurred in the delay compensation experiment. We confirmed that this problem was caused by valid bit-expression of the re-quantized data. To solve this problem, the novel method will be applied to VCS main product. The effectiveness of VCS trial product has been verified through the preliminary experimental results, but the overflow problem was occurred.

• Journal of Oriental Medical Thermology
• /
• v.7 no.1
• /
• pp.1-13
• /
• 2009

Purpose: To evaluate the hot flush relief efficacy of Yiseontang-gami in climacteric women with hot flushes, a vasomotor symptom. Methods: The 20 subjects who signing on the clinical trial written consent by self-will is registered this clinical trial after decided suitable by selection and exception standard, after take a medical experiment and checkup according to clinical trial plan. Registered subject should valuated by settled schedule after take the testing medicine(Yiseontang-gami)during thirty-day. The evaluating indexes of this trial are hot flush VAS, hot flush frequency, hot flush consistence time, sweating VAS, palpitation VAS, sleep disturbance VAS, MRS, MENQOL, PGA. Results: The results were as follows 1. 4 subjects dropped out of the clinical trial and 16 subjects completed it. 2. After Yiseontang-gami treatment, hot flush VAS, hot flush frequent, sweating VAS, Palpitation VAS, sleep disturbance VAS improved significantly. 3. After Yiseontang-gami treatment, hot flush consistence time was not improved significantly. 4. After Yiseontang-gami treatment, blood test value were not different significantly. Conclusion: In this clinical trial we consider that Yiseontang-gami is suitable treatment for the hot flushes and related symptoms.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1997.11a
• /
• pp.57-74
• /
• 1997

To make a proposal for the revision of KGCP, ICH Harmonized Tripartite Guideline for Good Clinical Practice, which is on the stage of worldwide implementation, was compared with current GCPs of tripartite countries of ICH, namely USA, Europe and Japan as well as Korea. On the basis of the classification in ICH GCP, comprehensive comparisons among the corresponding articles of 4 regions or countries were made in the order of IRB / IEC, Investigator, Sponsor and Clinical Trial Protocol. Based on the comparisons of the contents in ICH-GCP with those in current GCPs, major suggestions for the revision of current KGCP can be made as follows. Firstly, the function of IRB / IEC needs to be strengthened for the initiation and continuation of clinical trial. Current 2-step approval system of IRB / IEC and Health Authorities requires to be converted into the system similar to that of developed countries. Secondly, sponsor's obligation needs to be tightened to control and assure the quality of clinical trial. Inspection of regulatory authorities should be made to perform during and / or after clinical trial, when it is necessary. In other words, sponsor should be made to establish written Standard Operating Procedures (SOPs) for all aspects of clinical trial including monitoring to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, GCP, and the applicable regulatory requirement (s). Besides, the provision of ‘Quality Control and Quality Assurance’ should be added to the protocol to establish the credibility of the result of the clinical trial.